

Patricia ZÃ³iga GarcÃ-a

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5347396/publications.pdf>

Version: 2024-02-01

15
papers

828
citations

687363

13
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

2053
citing authors

#	ARTICLE	IF	CITATIONS
1	The metabolic co-regulator PGC1 β suppresses prostate cancer metastasis. <i>Nature Cell Biology</i> , 2016, 18, 645-656.	10.3	176
2	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	27.8	142
3	Different EV enrichment methods suitable for clinical settings yield different subpopulations of urinary extracellular vesicles from human samples. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 29497.	12.2	112
4	Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1470442.	12.2	103
5	Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation. <i>Cell Death and Differentiation</i> , 2015, 22, 131-144.	11.2	70
6	Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer. <i>Oncotarget</i> , 2016, 7, 6835-6846.	1.8	55
7	Stratification and therapeutic potential of PML in metastatic breast cancer. <i>Nature Communications</i> , 2016, 7, 12595.	12.8	45
8	Targeting PML in triple negative breast cancer elicits growth suppression and senescence. <i>Cell Death and Differentiation</i> , 2020, 27, 1186-1199.	11.2	26
9	PPAR γ Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. <i>Cancer Research</i> , 2018, 78, 399-409.	0.9	20
10	Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	19
11	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. <i>Methods</i> , 2015, 77-78, 25-30.	3.8	16
12	TRIB3 suppresses tumorigenesis by controlling mTORC2/AKT/FOXO signaling. <i>Molecular and Cellular Oncology</i> , 2015, 2, e980134.	0.7	16
13	Low-dose statin treatment increases prostate cancer aggressiveness. <i>Oncotarget</i> , 2018, 9, 1494-1504.	1.8	15
14	PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer. <i>Oncogenesis</i> , 2022, 11, 10.	4.9	6
15	470 Tumor Suppressive Activity of PPAR δ in Prostate Cancer. <i>European Journal of Cancer</i> , 2012, 48, S113.	2.8	0